Claims
- 1. A composition comprising an active agent and a di- or tripeptide selected from the group consisting of dileucine, leu-leu-gly, leu-leu-ala, leu-leu-val, leu-leu-leu, leu-leu-ile, leu-leu-met, leu-leu-pro, leu-leu-phe, leu-leu-trp, leu-leu-ser, leu-leu-thr, leu-leu-cys, leu-leu-tyr, leu-leu-asp, leu-leu-glu, leu-leu-lys, leu-leu-arg, leu-leu-his, leu-leu-nor, leu-gly-leu, leu-ala-leu, leu-val-leu, leu-ile-leu, leu-met-leu, leu-pro-leu, leu-phe-leu, leu-trp-leu, leu-ser-leu, leu-thr-leu, leu-cys-leu, leu-tyr-leu, leu-asp-leu, leu-glu-leu, leu-lys-leu, leu-arg-leu, leu-nor-leu, and combinations thereof.
- 2. The composition of claim 1, in aerosolized form.
- 3. The composition of claim 1, in liquid form.
- 4. The composition of claim 3, wherein the liquid is an aqueous solution.
- 5. The composition of claim 3, wherein the liquid is a suspension.
- 6. The composition of claim 3, further comprising a propellant.
- 7. The composition of claim 6, wherein the propellant is selected from the group consisting of a chlorofluorocarbon, a fluorocarbon, and combinations thereof.
- 8. The composition of claim 7, wherein the propellant comprises a chlorofluorocarbon or fluorocarbon.
- 9. The composition of claim 3, in aerosolized form.
- 10. The composition of claim 3, wherein the composition is suitable for delivery to the lung or deep lung by inhalation.
- 11. The composition of claim 10, wherein the composition is suitable for delivery via nebulization.
- 12. The composition of claim 3, wherein the liquid comprises a solvent.
- 13. The composition of claim 12, wherein the solvent is selected from the group consisting of water, ethanol, saline, and combinations thereof.
- 14. The composition of claim 1, wherein the di- or tripeptide is present in the composition from about 1% by weight to about 99% by weight.
- 15. The composition of claim 14, wherein the di- or tripeptide is present in the composition from about 2% by weight to about 75% by weight.
- 16. The composition of claim 15, wherein the di- or tripeptide is present in the composition from about 5% by weight to about 50% by weight.
- 17. The composition of claim 1, further comprising a pharmaceutically acceptable excipient or carrier.
- 18. The composition of claim 17, wherein the excipient is selected from the group consisting of carbohydrates, amino acids, peptides, proteins, organic acid salts, and polymers.
- 19. The composition of claim 1, comprising a dipeptide.
- 20. The composition of claim 19, wherein the dipeptide is dileucine.
- 21. The composition of claim 1, comprising a tripeptide.
- 22. The composition of claim 21, wherein the tripeptide is selected from the group consisting of leu-leu-leu, leu-leu-val, leu-leu-ile, leu-leu-trp, leu-leu-ala, leu-leu-met, leu-leu-phe, leu-leu-tyr, leu-leu-pro, leu-val-leu, leu-ile-leu, leu-trp-leu, leu-ala-leu, leu-met-leu, leu-phe-leu, leu-tyr-leu, leu-pro-leu, and combinations thereof.
- 23. The composition of claim 22, wherein the tripeptide is trileucine.
- 24. The composition of claim 1, wherein said active agent is selected from the group consisting of insulin, cyclosporin, parathyroid hormone, follicle stimulating hormone, VLA-4 inhibitors, interleukin-4R, thrombopoietin, c-peptide, amylin, pro-insulin, interleukin-1, interleukin-2, alpha-1-antitrypsin, budesonide, human growth hormone, growh hormone releasing hormone, interferon alpha, interferon beta, growth colony stimulating factor, keratinocyte growth factor, glial growth factor, tumor necrosis factor, leutinizing hormone releasing hormone, calcitonin, low molecular weight heparin, somatostatin, respiratory syncytial virus antibody, erythropoietin, Factor VIII, Factor IX, ceredase, cerezyme and analogues, agonists and antagonists thereof.
- 25. The composition of claim 1, in a dry powder form.
- 26. The composition of claim 25, wherein the dry powder is a spray-dried powder.
- 27. A method for treating a mammalian subject suffering from a condition that is responsive to an active agent comprising administering to the subject a composition comprised of a therapeutically effective amount of the active agent and a di- or tripeptide selected from the group consisting of dileucine, leu-leu-gly, leu-leu-ala, leu-leu-val, leu-leu-leu, leu-leu-ile, leu-leu-met, leu-leu-pro, leu-leu-phe, leu-leu-trp, leu-leu-ser, leu-leu-thr, leu-leu-cys, leu-leu-tyr, leu-leu-asp, leu-leu-glu, leu-leu-lys, leu-leu-arg, leu-leu-his, leu-leu-nor, leu-gly-leu, leu-ala-leu, leu-val-leu, leu-ile-leu, leu-met-leu, leu-pro-leu, leu-phe-leu, leu-trp-leu, leu-ser-leu, leu-thr-leu, leu-cys-leu, leu-tyr-leu, leu-asp-leu, leu-glu-leu, leu-lys-leu, leu-arg-leu, leu-nor-leu, and combinations thereof.
CROSS REFERENCE TO RELATED APPLICATIONS
This application is a continuation of U.S. patent application Ser. No. 09/548,759, filed Apr. 13, 2000, now U.S. Pat. No. 6,518,239 which claims the benefit of priority of the following U.S. Provisional Patent Applications: Ser. No. 60/162,451 filed on Oct. 29, 1999; Ser. No. 60/164,236 filed on Nov. 8, 1999; Ser. No. 60/172,769 filed on Dec. 20, 1999; Ser. No. 60/178,383 filed on Jan. 27, 2000; and Ser. No. 60/178,415 filed on Jan. 27, 2000, all of which are incorporated herein by reference in their entirety.
US Referenced Citations (2)
Number |
Name |
Date |
Kind |
5182258 |
Chiou |
Jan 1993 |
A |
6518239 |
Kuo et al. |
Feb 2003 |
B1 |
Foreign Referenced Citations (2)
Number |
Date |
Country |
WO 9621461 |
Jul 1996 |
WO |
WO 9703649 |
Feb 1997 |
WO |
Provisional Applications (5)
|
Number |
Date |
Country |
|
60/178415 |
Jan 2000 |
US |
|
60/178383 |
Jan 2000 |
US |
|
60/172769 |
Dec 1999 |
US |
|
60/164236 |
Nov 1999 |
US |
|
60/162451 |
Oct 1999 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
09/548759 |
Apr 2000 |
US |
Child |
10/313343 |
|
US |